NCT02301117 - A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 19, 2019

Study Completion Date

June 19, 2019

Conditions

Advanced Solid Tumors

Interventions

DRUG

TAS-102

Trial Locations (14)

Belgrade Clinical Site, Belgrade

Pittsburgh Clinical Site, Pittsburgh

Sremska Kamenica Clinical Site, Kamenitz

Baltimore Clinical Site, Baltimore

Gainesville Clinical Site, Gainesville

Cleveland Clinical Site, Cleveland

Cleveland Clinical Site, Cleveland

Dallas Clinical Site, Dallas

Phoenix Clinical Site, Phoenix

Santa Monica Clinical Site, Santa Monica

Duarte Clinical Site, Duarte

Boston Clinical Site, Boston

Brno Clinical Site, Brno

Praha Clinical Site, Prague

All Listed Sponsors

lead

Taiho Oncology, Inc.

INDUSTRY